IL122025A - Use of raloxifene or pharmaceutically acceptable salts or solvates thereof, in the preparation of a medicament for preventing breast cancer - Google Patents

Use of raloxifene or pharmaceutically acceptable salts or solvates thereof, in the preparation of a medicament for preventing breast cancer

Info

Publication number
IL122025A
IL122025A IL12202597A IL12202597A IL122025A IL 122025 A IL122025 A IL 122025A IL 12202597 A IL12202597 A IL 12202597A IL 12202597 A IL12202597 A IL 12202597A IL 122025 A IL122025 A IL 122025A
Authority
IL
Israel
Prior art keywords
raloxifene
solvates
medicament
preparation
pharmaceutically acceptable
Prior art date
Application number
IL12202597A
Other languages
English (en)
Other versions
IL122025A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27268608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL122025(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9624800.0A external-priority patent/GB9624800D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Priority to IL15208097A priority Critical patent/IL152080A/en
Publication of IL122025A0 publication Critical patent/IL122025A0/xx
Priority to IL15208002A priority patent/IL152080A0/xx
Publication of IL122025A publication Critical patent/IL122025A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL12202597A 1996-10-30 1997-10-27 Use of raloxifene or pharmaceutically acceptable salts or solvates thereof, in the preparation of a medicament for preventing breast cancer IL122025A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IL15208097A IL152080A (en) 1996-10-30 1997-10-27 Use of raloxifene or pharmaceutically acceptable salts or solvates thereof in the preparation of a medicament for preventing breast cancer
IL15208002A IL152080A0 (en) 1996-10-30 2002-10-02 Use of raloxifene or pharmaceutically acceptable salts or solvates thereof, in the preparation of a medicament for preventing breast cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2985096P 1996-10-30 1996-10-30
GBGB9624800.0A GB9624800D0 (en) 1996-11-29 1996-11-29 Methods of preventing breast cancer
US4026097P 1997-03-10 1997-03-10

Publications (2)

Publication Number Publication Date
IL122025A0 IL122025A0 (en) 1998-03-10
IL122025A true IL122025A (en) 2003-01-12

Family

ID=27268608

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12202597A IL122025A (en) 1996-10-30 1997-10-27 Use of raloxifene or pharmaceutically acceptable salts or solvates thereof, in the preparation of a medicament for preventing breast cancer
IL12202697A IL122026A0 (en) 1996-10-30 1997-10-27 Improvements in or relating to the prophylaxis of breast cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL12202697A IL122026A0 (en) 1996-10-30 1997-10-27 Improvements in or relating to the prophylaxis of breast cancer

Country Status (43)

Country Link
US (2) US6303634B1 (cs)
EP (3) EP1369115B1 (cs)
JP (2) JPH10147530A (cs)
CN (2) CN1182590A (cs)
AP (1) AP971A (cs)
AR (2) AR010538A1 (cs)
AT (2) ATE239475T1 (cs)
AU (3) AU5005697A (cs)
BE (2) BE1011381A5 (cs)
BG (1) BG63841B1 (cs)
BR (1) BR9712703A (cs)
CA (2) CA2219070C (cs)
CH (2) CH693820A5 (cs)
CZ (2) CZ300261B6 (cs)
DE (2) DE69721692T2 (cs)
DK (2) DK0839532T3 (cs)
EA (2) EA002054B1 (cs)
EE (1) EE03663B1 (cs)
ES (4) ES2135342B1 (cs)
FR (2) FR2755014B1 (cs)
GB (3) GB2318734B (cs)
GE (1) GEP20032910B (cs)
GR (2) GR1003189B (cs)
HU (2) HUP9701777A3 (cs)
IE (2) IE970773A1 (cs)
IL (2) IL122025A (cs)
IS (1) IS5035A (cs)
IT (2) IT1298470B1 (cs)
LU (2) LU90157B1 (cs)
LV (1) LV12353B (cs)
MY (1) MY121623A (cs)
NL (2) NL1007387C2 (cs)
NO (2) NO322468B1 (cs)
NZ (1) NZ329042A (cs)
PT (2) PT839532E (cs)
RO (1) RO120813B1 (cs)
SG (2) SG72765A1 (cs)
SI (3) SI20107A (cs)
SK (1) SK287047B6 (cs)
TR (1) TR199900951T2 (cs)
UA (1) UA46762C2 (cs)
WO (2) WO1998018449A1 (cs)
YU (1) YU42397A (cs)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
GB9624800D0 (en) * 1996-11-29 1997-01-15 Lilly Co Eli Methods of preventing breast cancer
FI109332B (fi) 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
FI982733A7 (fi) * 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
ES2236536T3 (es) 2001-05-22 2005-07-16 Eli Lilly And Company Derivados tetrahidroquinolino para la inhibicion de enfermedades asociadas con la privacion de estrogenos o con una respuesta fisiologica aberrante a estrogenos endogenos.
WO2002094788A1 (en) 2001-05-22 2002-11-28 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
US20040225200A1 (en) * 2003-05-09 2004-11-11 Edmundson Catherine M. System and method of analyzing the health of a population
GR1005694B (el) * 2005-06-08 2007-10-22 Αλεξης Μιχαηλ Ιστοειδικα αντιοιστρογονα ειδικα για τον αλφα υποδοχεα των οιστρογονων
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN102973573B (zh) * 2012-11-28 2015-04-08 玉林师范学院 一种人乳腺癌细胞抑制剂及制备方法
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
CN116650484A (zh) * 2023-05-11 2023-08-29 南通大学 一种乳腺癌相关蛋白的抑制剂及其应用
WO2025099484A1 (en) * 2023-11-06 2025-05-15 Centro De Investigación Y De Estudios Avanzados Del I.P.N. Use of loratadine for the treatment of hepatic cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
PT652004E (pt) * 1993-10-15 2002-10-31 Lilly Co Eli Metodos para tratar neoplasmas resistentes
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
IL112746A (en) * 1994-03-02 1999-12-31 Lilly Co Eli Orally administrable pharmaceutical formulation comprising raloxifene hydrochoride
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5521214A (en) * 1995-01-25 1996-05-28 Eli Lilly And Company Methods of inhibiting environmental estrogens
US5821254A (en) 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
CZ300341B6 (cs) * 1996-03-26 2009-04-22 Eli Lilly And Company Farmaceutická kompozice obsahující raloxifen

Also Published As

Publication number Publication date
ES2135342B1 (es) 2000-05-16
WO1998018325A1 (en) 1998-05-07
EP1369115B1 (en) 2006-09-06
IL122025A0 (en) 1998-03-10
CH693820A5 (fr) 2004-02-27
EP1369115A1 (en) 2003-12-10
SG83672A1 (en) 2001-10-16
DE69721692D1 (de) 2003-06-12
GR1003189B (el) 1999-09-01
ITMI972434A1 (it) 1999-04-29
AP9901494A0 (en) 1999-03-31
NL1007386C2 (nl) 1998-05-14
SK287047B6 (sk) 2009-10-07
MY121623A (en) 2006-02-28
BR9712703A (pt) 1999-10-26
CN1182590A (zh) 1998-05-27
DE69736644T2 (de) 2007-10-25
HUP9701777A3 (en) 1999-07-28
AR010538A1 (es) 2000-06-28
PT839532E (pt) 2003-09-30
AU5005697A (en) 1998-05-22
AR013864A1 (es) 2001-01-31
DE69736644D1 (de) 2006-10-19
GB9911557D0 (en) 1999-07-21
NO974972L (no) 1998-05-04
EP0839532B1 (en) 2003-05-07
NO974972D0 (no) 1997-10-28
FR2755014B1 (fr) 1999-02-05
CH691847A5 (fr) 2001-11-15
HUP9701777A2 (hu) 1999-06-28
CZ300261B6 (cs) 2009-04-01
IE970773A1 (en) 2000-02-09
CN1182591A (zh) 1998-05-27
MX9708341A (es) 1998-08-30
GEP20032910B (en) 2003-03-25
EP0839533A1 (en) 1998-05-06
NO322468B1 (no) 2006-10-09
GB9722796D0 (en) 1997-12-24
IS5035A (is) 1999-04-27
UA46762C2 (uk) 2002-06-17
US20020019418A1 (en) 2002-02-14
AP971A (en) 2001-05-30
TR199900951T2 (xx) 1999-07-21
CA2219070C (en) 2007-12-18
BE1011382A5 (fr) 1999-08-03
IL122026A0 (en) 1998-03-10
HUP9701778A3 (en) 1999-06-28
ES2271476T3 (es) 2007-04-16
RO120813B1 (ro) 2006-08-30
BE1011381A5 (fr) 1999-08-03
AU4364797A (en) 1998-05-07
EA006083B1 (ru) 2005-08-25
EE03663B1 (et) 2002-04-15
LU90158B1 (fr) 1998-06-02
MX9708340A (es) 1998-08-30
CZ341297A3 (cs) 1998-05-13
GB9722801D0 (en) 1997-12-24
LU90157B1 (fr) 1998-06-02
EE9900162A (et) 1999-12-15
FR2756490A1 (fr) 1998-06-05
IT1298470B1 (it) 2000-01-10
JPH10147530A (ja) 1998-06-02
WO1998018449A1 (en) 1998-05-07
BG63841B1 (bg) 2003-03-31
NO974973D0 (no) 1997-10-28
HK1010495A1 (en) 1999-06-25
ATE338551T1 (de) 2006-09-15
US6303634B1 (en) 2001-10-16
CA2219377A1 (en) 1998-04-30
CA2219070A1 (en) 1998-04-30
ES2135342A1 (es) 1999-10-16
DE69721692T2 (de) 2004-03-25
AU4364897A (en) 1998-05-07
SG72765A1 (en) 2000-05-23
FR2755014A1 (fr) 1998-04-30
SI1369115T1 (sl) 2006-12-31
CZ341197A3 (cs) 1998-05-13
DK0839532T3 (da) 2003-08-25
FR2756490B1 (fr) 2003-06-20
DK1369115T3 (da) 2007-01-02
ES2135343A1 (es) 1999-10-16
YU42397A (sh) 2000-10-30
LV12353B (en) 2000-02-20
LV12353A (lv) 1999-10-20
JPH10147529A (ja) 1998-06-02
GB2318734A (en) 1998-05-06
SK55999A3 (en) 2000-06-12
EA200100716A1 (ru) 2002-06-27
ATE239475T1 (de) 2003-05-15
SI20107A (sl) 2000-06-30
AU731388B2 (en) 2001-03-29
GR970100409A (el) 1998-06-30
ES2197312T3 (es) 2004-01-01
EP0839532A1 (en) 1998-05-06
HUP9701778A2 (hu) 1999-01-28
AU5005197A (en) 1998-05-22
EA002054B1 (ru) 2001-12-24
EA199900431A1 (ru) 1999-10-28
GR970100408A (el) 1998-06-30
HU9701777D0 (en) 1997-12-29
HU9701778D0 (en) 1997-12-29
PT1369115E (pt) 2006-12-29
NZ329042A (en) 1999-08-30
ITMI972433A1 (it) 1999-04-29
BG103369A (en) 2000-05-31
GB2318733A (en) 1998-05-06
NL1007387C2 (nl) 1998-05-14
GB2318734B (en) 1999-12-01
SI0839532T1 (en) 2003-10-31
IE970772A1 (en) 2000-02-09

Similar Documents

Publication Publication Date Title
IL122025A (en) Use of raloxifene or pharmaceutically acceptable salts or solvates thereof, in the preparation of a medicament for preventing breast cancer
PL299814A1 (en) Pharmaceutical preparation inhibiting depletion of human bone tissue
AU2768699A (en) Lesion localizer for nuclear medicine
IL144668A (en) Use of a 4-h-1-benzopyran-4-one derivative for the preparation of a medicament for inhibiting smooth muscle cell proliferation
LU88842I2 (fr) Nebivolol optionnellement sous forme d'un sel ou d'un hydrate pharmaceutiquement acceptable en particulier hydroclorure de Nebivolol
IL145150A0 (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
IL137186A0 (en) Device for inhaling medicament
AU650484B2 (en) Isoxazole compound, pharmaceutically acceptable salt thereof, and medicinal use thereof
GB9418064D0 (en) Medicament administration inhaler
HUP9802677A3 (en) Use of 1,2,4-triazole derivatives for the manufacture of a medicament for the treatment of cancers
EP0437729A3 (en) New peptides, procedure for their preparation and their use as a medicament, especially their use as medicament against retroviruses
ZA974148B (en) Administration of histamine for therapeutic purposes.
PL307469A1 (en) Preparation for oral administration
HU9602908D0 (en) X-ray contrast compositions containing pharmaceutically acceptable clays
IL152080A0 (en) Use of raloxifene or pharmaceutically acceptable salts or solvates thereof, in the preparation of a medicament for preventing breast cancer
GB8911259D0 (en) Inhalation medicament
PL325509A1 (en) Therapeutic agent for oral administration
EP0459198A3 (en) Thioalkanones, procedure for their preparation and their use
HUP0103864A3 (en) Use of 3-(1h-imidazol-4-ylmethyl)-indan-5-ol in the manufacture of a medicament for intraspinal administration
IL149653A0 (en) 2-arylquinoline derivatives, preparation and therapeutic use thereof
EG19689A (en) New pharmaceutical preparation for oral use
GB2251620B (en) (S)-11-Hydroxy-10-methylaporphine, its physiologically acceptable salts and pharmaceutical compositions thereof
CS231590A3 (en) Preparation for hemorrhoids treatment
TW352510U (en) Panties used for old person or patient
RU97118477A (ru) Применение ралоксифена или его фармацевтически приемлемой соли в профилактике рака молочной железы

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired